

## Freedom of Information Request

**Q1. Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:**

- Adalimumab – Humira: **19**
- Adalimumab Biosimilar: **60**
- Apremilast: **unable to quantify**
- Brodalumab: **1**
- Certolizumab: **1**
- Dimethyl fumarate: **unable to quantify**
- Etanercept Enbrel: **1**
- Etanercept Biosimilar: **4**
- Guselkumab: **3**
- Infliximab – Remicade: **0**
- Infliximab Biosimilar: **2**
- Ixekizumab: **10**
- Risankizumab: **4**
- Secukinumab: **8**
- Tildrakizumab: **0**
- Ustekinumab: **54**

**Q2. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:**

- Adalimumab – Humira: **38**
- Adalimumab Biosimilar: **186**
- Golimumab: **5**
- Infliximab – Remicade: **29**
- Infliximab Biosimilar: **147**
- Tofacitinib: **15**
- Ustekinumab: **48**
- Vedolizumab: **79**

**Q3. If possible, could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department for Ulcerative Colitis ONLY with the following biologic drugs:**

- Adalimumab – Humira: **5**
- Adalimumab Biosimilar: **68**
- Golimumab: **5**
- Infliximab – Remicade: **5**
- Infliximab Biosimilar: **53**
- Tofacitinib: **15**
- Ustekinumab: **7**
- Vedolizumab: **44**

**Please note that the Trust is unable to quantify Apremilast and dimethyl fumarate as most of the new prescribing of Apremilast has been taken over by the GPs**